http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2524015-T3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9f935b84827ff4a3e441c3f219d841de |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96486 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate | 2006-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2014-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d66d62093629dba6e5378b8bd088edcd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8d34b074a08d9b5a6aa5afa112cdf95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc714d58a9d2794b882371032b77a40a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81b45d4e3cfef3b2da753a7a9a73557a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de2c755515c82bf2cae796dd44072147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09a5817d94b70252678644bc0d7246f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2fb437a13b6029f0f435d59f3305acd |
publicationDate | 2014-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-2524015-T3 |
titleOfInvention | Metalloproteinase binding proteins |
abstract | An isolated protein comprising a heavy chain immunoglobulin variable domain (HC) sequence and a light chain immunoglobulin variable domain (LC) sequence, wherein the HC and LC immunoglobulin variable domain sequences form a binding site to the antigen that binds to, and inhibits an MMP-14; wherein the HC immunoglobulin variable domain sequence comprises a complementarity determining region of HC (CDR) 1, CDR2, and CDR3 and the LC immunoglobulin variable domain sequence comprises a CDR1, CDR2, and CDR3 of LC, and wherein the immunoglobulin variable domain sequences comprise the following (i) the HC CDR1 sequence comprises residues 31-35 of SEQ ID NO: 156, the HC CDR2 sequence comprises residues 50-66 of SEQ ID NO: 156, and the CDR3 sequence of HC comprises residues 99-104 of SEQ ID NO: 156; and the LC CDR1 sequence comprises residues 25-35 of SEQ ID NO: 157, the LC CDR2 sequence comprises residues 51-57 of SEQ ID NO: 157, and the LC CDR3 sequence comprises the residues 90-99 of SEQ ID NO: 157; (ii) the CDR1 sequence of HC comprises residues 31-35 of SEQ ID NO: 144, the CDR2 sequence of HC comprises residues 50-66 of SEQ ID NO: 144, and the CDR3 sequence of HC comprises waste 99-115 of SEQ ID NO: 144; and the CDR1 sequence of LC comprises residues 25-40 of SEQ ID NO: 145, the CDR2 sequence of LC comprises residues 56-62 of SEQ ID NO: 145, and the CDR3 sequence of LC comprises the residues 95-103 of SEQ ID NO: 145; (iii) the CDR1 sequence of HC comprises residues 31-35 of SEQ ID NO: 146, the CDR2 sequence of HC comprises residues 50-66 of SEQ ID NO: 146, and the CDR3 sequence of HC comprises residues 99-114 of SEQ ID NO: 146; the CDR1 sequence of LC comprises residues 23-35 of SEQ ID NO: 147, the CDR2 sequence of LC comprises residues 51-57 of SEQ ID NO: 147, and the CDR3 sequence of LC comprises residues 90 - 101 of SEQ ID NO: 147; (iv) the HC CDR1 sequence comprises residues 31-35 of SEQ ID NO: 148, the HC CDR2 sequence comprises residues 50-66 of SEQ ID NO: 148, and the HC CDR3 sequence comprises residues 99-109 of SEQ ID NO: 148; and the LC CDR1 sequence comprises residues 25-35 of SEQ ID NO: 149, the LC CDR2 sequence comprises residues 51-57 of SEQ ID NO: 149, and the LC CDR3 sequence comprises the residues 90-98 of SEQ ID NO: 149; (v) the CDR1 sequence of HC comprises residues 31-35 of SEQ ID NO: 150, the CDR2 sequence of HC comprises residues 50-66 of SEQ ID NO: 150, and the CDR3 sequence of HC comprises waste 99-114 of SEQ ID NO: 150; and the CDR1 sequence of LC comprises residues 25-40 of SEQ ID NO: 151, the CDR2 sequence of LC comprises residues 56-62 of SEQ ID NO: 151, and the CDR3 sequence of LC comprises the residues 95-103 of SEQ ID NO: 151; (vi) the CDR1 sequence of HC comprises residues 31-35 of SEQ ID NO: 152, the CDR2 sequence of HC comprises residues 50-66 of SEQ ID NO: 152, and the CDR3 sequence of HC comprises waste 99-114 of SEQ ID NO: 152; and the LC CDR1 sequence comprises residues 25-35 of SEQ ID NO: 153, the LC CDR2 sequence comprises residues 51-57 of SEQ ID NO: 153, and the LC CDR3 sequence comprises the residues 90-98 of SEQ ID NO: 153; (vii) the HC CDR1 sequence comprises residues 31-35 of SEQ ID NO: 154, the CDR2 sequence of HC comprises residues 50-66 of SEQ ID NO: 154, and the HC CDR3 sequence comprises waste 99-107 of SEQ ID NO: 154; and the LC CDR1 sequence comprises residues 25-36 of SEQ ID NO: 155, the LC CDR2 sequence comprises residues 52-58 of SEQ ID NO: 155, and the LC CDR3 sequence comprises the residues 91-99 of SEQ ID NO: 155; (viii) the HC CDR1 sequence comprises residues 31-35 of SEQ ID NO: 158, the CDR2 sequence of HC comprises residues 50-66 of SEQ ID NO: 158, and the CDR3 sequence of HC comprises waste 99-108 of SEQ ID NO: 158; and the LC CDR1 sequence comprises residues 25-36 of SEQ ID NO: 159, the LC CDR2 sequence comprises residues 52-58 of SEQ ID NO: 159, and the LC CDR3 sequence comprises the residues 91-98 of SEQ ID NO: 159. |
priorityDate | 2005-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1073.